SLX 0953
Alternative Names: SLX-0953Latest Information Update: 08 Dec 2023
Price :
$50 *
At a glance
- Originator Biolexis Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 modulators; MELK protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 10 Oct 2023 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route), before October 2023 (Biolexis Therapeutics pipeline, October 2023)
- 10 Oct 2023 Biolexis Therapeutics plans to file IND for Acute myeloid leukaemia in Q4 2024 (Biolexis Therapeutics pipeline, October 2023)
- 10 Oct 2023 Biolexis Therapeutics plans a phase I trial for Acute myeloid leukaemia in Q1 2025 (Biolexis Therapeutics pipeline, October 2023)